Anastasia N. Tikhonova

Anastasia N. Tikhonova

Auto-generated profile, based on publicly available information

Anastasia N. Tikhonova

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Science
Verified
Journal Article
Closed access
PKPiotr Konieczny
Piotr Konieczny
YXYue Xing
Yue Xing
ISIkjot Sidhu
Ikjot Sidhu
ISIpsita Subudhi
Ipsita Subudhi
KMKody P. Mansfield
Kody P. Mansfield
SNShruti Naik
Shruti Naik
Mammalian cells autonomously activate hypoxia-inducible transcription factors (HIFs) to ensure survival in low-oxygen environments. We report here that injury-induced hypoxia is insufficient to trigger HIF1α in damaged epithelium. Instead, multimodal single-cell and spatial transcriptomics analyses and functional studies reveal that retinoic acid–related orphan receptor γt + (RORγt + ) γδ T cell–derived interleukin-17A (IL-17A) is necessary and sufficient to activate HIF1α. Protein kinase B (AKT) and extracellular signal–regulated kinase 1/2 (ERK1/2) signaling proximal of IL-17 receptor C (IL-17RC) activates mammalian target of rapamycin (mTOR) and consequently HIF1α. The IL-17A–HIF1α axis drives glycolysis in wound front epithelia. Epithelial-specific loss of IL-17RC, HIF1α, or blockade of glycolysis derails repair. Our findings underscore the coupling of inflammatory, metabolic, and migratory programs to expedite epithelial healing and illuminate the immune cell–derived inputs in cellular adaptation to hypoxic stress during repair.

29 December 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ALAudrey Lasry
Audrey Lasry
BNBettina Nadorp
Bettina Nadorp
MFMaarten Fornerod
Maarten Fornerod
DNDeedra Nicolet
Deedra Nicolet
HWHuiyun Wu
Huiyun Wu
IAIannis Aifantis
Iannis Aifantis

12 March 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
IDIgor Dolgalev
Igor Dolgalev
ATAnastasia N. Tikhonova
Anastasia N. Tikhonova
Single-cell sequencing approaches have transformed our understanding of stem cell systems, including hematopoiesis and its niche within the bone marrow. Recent reports examined the bone marrow microenvironment at single-cell resolution at steady state, following chemotherapy treatment, leukemic onset, and aging. These rapid advancements significantly informed our understanding of bone marrow niche heterogeneity. However, inconsistent representation and nomenclature among the studies hinder a comprehensive interpretation of this body of work. Here, we review recent reports interrogating bone marrow niche architecture and present an integrated overview of the published datasets.

19 January 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ALAudrey Lasry
Audrey Lasry
BNBettina Nadorp
Bettina Nadorp
MFMaarten Fornerod
Maarten Fornerod
DNDeedra Nicolet
Deedra Nicolet
HWHuiyun Wu
Huiyun Wu
IAIannis Aifantis
Iannis Aifantis

25 September 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
VRVincent Rondeau
Vincent Rondeau
JBJacob M. Berman
Jacob M. Berman
TLTianyi Ling
Tianyi Ling
COCristiana O’bRien
Cristiana O’bRien
RCRachel Culp-Hill
Rachel Culp-Hill
CJCourtney L. Jones
Courtney L. Jones
Acute myeloid leukemia (AML) is a devastating disease initiated and maintained by a rare subset of cells called leukemia stem cells (LSCs). LSCs are responsible for driving disease relapse, making the development of new therapeutic strategies to target LSCs urgently needed. The use of mass spectrometry–based metabolomics profiling has enabled the discovery of unique and targetable metabolic properties in LSCs. However, we do not have a comprehensive understanding of metabolite differences between LSCs and their normal counterparts, hematopoietic stem and progenitor cells (HSPCs). In this study, we used an unbiased mass spectrometry–based metabolomics analysis to define differences in metabolites between primary human LSCs and HSPCs, which revealed that LSCs have a distinct metabolome. Spermidine was the most enriched metabolite in LSCs compared with HSPCs. Pharmacological reduction of spermidine concentrations decreased LSC function but spared normal HSPCs. Polyamine depletion also decreased leukemic burden in patient-derived xenografts. Mechanistically, spermidine depletion induced LSC myeloid differentiation by decreasing eIF5A-dependent protein synthesis, resulting in reduced expression of a select subset of proteins. KAT7, a histone acetyltransferase, was one of the top candidates identified to be down-regulated by spermidine depletion. Overexpression of KAT7 partially rescued polyamine depletion–induced decreased colony-forming ability, demonstrating that loss of KAT7 is an essential part of the mechanism by which spermidine depletion targets AML clonogenic potential. Together, we identified and mechanistically dissected a metabolic vulnerability of LSCs that has the potential to be rapidly translated into clinical trials to improve outcomes for patients with AML.

1 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MGMark Gower
Mark Gower
XLXiming Li
Ximing Li
AAAlicia G. Aguilar-Navarro
Alicia G. Aguilar-Navarro
BLBrian Lin
Brian Lin
MFMinerva Fernandez
Minerva Fernandez
ATAnastasia N. Tikhonova
Anastasia N. Tikhonova
T-lineage acute lymphoblastic leukemia (ALL) is an aggressive cancer comprising diverse subtypes that are challenging to stratify using conventional immunophenotyping. To gain insights into subset-specific therapeutic vulnerabilities, we performed an integrative multiomics analysis of bone marrow samples from newly diagnosed T cell ALL, early T cell precursor ALL, and T/myeloid mixed phenotype acute leukemia. Leveraging cellular indexing of transcriptomes and epitopes in conjunction with T cell receptor sequencing, we identified a subset of patient samples characterized by activation of inflammatory and stem gene programs. These inflammatory T-lineage samples exhibited distinct biological features compared with other T-lineage ALL samples, including the production of proinflammatory cytokines, prevalence of mutations affecting cytokine signaling and chromatin remodeling, an altered immune microenvironment, and poor treatment responses. Moreover, we found that, although inflammatory T-lineage ALL samples were less sensitive to dexamethasone, they exhibited unique sensitivity to a BCL-2 inhibitor, venetoclax. To facilitate classification of patients with T-lineage ALL, we developed a computational inflammatory gene signature scoring system, which stratified patients and was associated with disease prognosis in three additional patient cohorts. By identifying a high-risk T-lineage ALL subtype on the basis of an inflammatory score, our study provides a framework for targeted therapeutic approaches for these challenging-to-treat cancers.